Full Text View
Tabular View
Study Results
Related Studies
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
This study has been completed.
Study NCT00589914   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

First Received on December 21, 2007.   Last Updated on February 3, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
RISPERDAL CONSTA
Paliperidone palmitate
Additional drug interventions recognized in this trial
9-hydroxy-risperidone
Risperidone
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services